Colloidal drug delivery systems: Current status and future directions

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 32, Issue 2, 2015, Pages 89-147

  Garg, Tarun ^a,b   Rath, Goutam ^a,b   Goyal, Amit K ^a,b  

^a ISF COLLEGE OF PHARMACY   (India)

^b I K GUJRAL PUNJAB TECHNICAL UNIVERSITY   (India)

Author keywords

Cell delivery; Liposomes; Niosomes; Particulate drug delivery; Resealed erythrocytes; Vesicular drug delivery

Indexed keywords

BENZOYL PEROXIDE; CISPLATIN; CLINDAMYCIN; COCHLEATE; CUBOSOME; DENDRIMER; DEXAMETHASONE; DOXYCYCLINE; DRUG CARRIER; ETHOSOME; FLUCONAZOLE; GEMCITABINE; GLYCYRRHETINIC ACID PHOSPHOLIPID COMPLEX; HAIR DYE; ISCOM; LEVODOPA; LIPOSOME; LIPOSPHERE; MICROPARTICLE; NANOPARTICLE; NAVELBINE; NIOSOME; RESVERATROL; RHODAMINE; SAQUINAVIR; SUPEROXIDE DISMUTASE; TIMOLOL MALEATE; TRANSFEROSOME; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIROSOME; COLLOID; DRUG;

ARTICLE; COLLOIDAL DRUG DELIVERY SYSTEM; DRUG DELIVERY SYSTEM; ENZYMATIC DEGRADATION; GENE TARGETING; HUMAN; MICELLE; MICROEMULSION; PARTICULATE DRUG DELIVERY SYSTEM; RESEALED ERYTHROCYTE; SELF EMULSIFYING DRUG DELIVERY SYSTEM; VESICULAR DRUG DELIVERY SYSTEM; BIOLOGICAL THERAPY; CLASSIFICATION; COLLOID; FORECASTING; MOLECULARLY TARGETED THERAPY; PHARMACOLOGY; PROCEDURES; TRENDS;

BIOLOGICAL THERAPY; COLLOIDS; DRUG DELIVERY SYSTEMS; FORECASTING; HUMANS; LIPOSOMES; MOLECULAR TARGETED THERAPY; PHARMACEUTICAL PREPARATIONS;

EID: 84983094936     PISSN: 07434863     EISSN: 2162660X     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.2015010159     Document Type: Article

References (407)

1. Ali Khan A, Mudassir J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipidbased nanoformulations. Int J Nanomedicine. 2013;8:2733–44.
2. Garg Tarun, Singh Onkar, Arora Saahil, RSR M. patented microencapsulation techniques and its application. J Pharm Res. 2011;4(7):2097–102.
3. Kaur M, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit Rev Ther Drug Carrier Syst. 2014;31(1):49–88.
4. Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target. 2012;20(10):813–30.
5. Beija M, Salvayre R, Lauth-de Viguerie N, Marty JD. Colloidal systems for drug delivery: from design to therapy. Trends Biotechnol. 2012;30(9):485–96.
6. Gagandeep, Garg T, Malik B, Rath G, Goyal AK. Development and characterization of nano-fiber patch for the treatment of glaucoma. Eur J Pharm Sci. 2014;53:10–6.
7. Arora N, Garg T, Bilandi A. Advances In Protein Stability. J Pharm Res. 2012;5(4):2072.
8. Garg T, Singh O, Arora S, Murthy R. Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst. 2012;29(1):1–63.
9. Arora N, Singh K, Garg T. A review on the cryopreservation technology and cryoprotectant. J Pharm Res. 2012;5(4):2087–90.
10. Arora N, Singh K, Garg T. Areas of nanomedicine applications. Int J Universal Pharm and Life Sci. 2012;2(1):216–27.
11. Elizondo E, Moreno E, Cabrera I, Cordoba A, Sala S, Veciana J. Liposomes and other vesicular systems: structural characteristics, methods of preparation, and use in nanomedicine. Prog Mol Biol Transl Sci. 2011;104:1–52.
12. Cosco D, Celia C, Cilurzo F, Trapasso E, Paolino D. Colloidal carriers for the enhanceddelivery through the skin. Expert Opin Drug Deliv. 2008;5(7):737–55.
13. Garg T, Goyal AK. Biomaterial-based scaffolds--current status and future directions. Expert Opin Drug Deliv. 2014;11(5):767–89.
14. Garg T. An evolutionary approaches in development of needle free injection technologies. Int J Pharm Pharmaceut Sci. 2012;4(1):590–6.
15. Garg T, Goyal AK. Liposomes: Targeted and Controlled Delivery System. Drug Deliv Letts. 2014;4(1):62–71.
16. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Rep. 2012;64(5):1020–37.
17. Swaminathan J, Ehrhardt C. Liposomal delivery of proteins and peptides. Expert Opin Drug Deliv. 2012;9(12):1489–503.
18. Amadi ST, Koteiche HA, Mishra S, McHaourab HS. Structure, dynamics, and substrate-induced conformational changes of the multidrug transporter EmrE in liposomes. J Biol Chem. 2010;285(34):26710–18.
19. Chen MH, Soda Y, Izawa K, Kobayashi S, Tani K, Maruyama K. A versatile drug delivery system using streptavidin-tagged pegylated liposomes and biotinylated biomaterials. Int J Pharm. 2013;454(1):478–85.
20. Al-Jamal WT, Kostarelos K. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res. 2011;44(10):1094–104.
21. Gabizon A. Liposomes as a drug delivery system in cancer chemotherapy. Horiz Biochem Biophys. 1989;9:185–211.
22. Vanic Z, Hurler J, Ferderber K, Golja Gasparovic P, Skalko-Basnet N, Filipovic-Grcic J. Novel vaginal drug delivery system: deformable propylene glycol liposomes-in-hydrogel. J Liposome Res. 2013.
23. Arai T, Benny O, Joki T, Menon LG, Machluf M, Abe T. Novel local drug delivery system using thermoreversible gel in combination with polymeric microspheres or liposomes. Anticancer Res. 2010;30(4):1057–64.
24. Goyal G, Garg T, Malik B, Chauhan G, Rath G, Goyal AK. Development and characterization of niosomal gel for topical delivery of benzoyl peroxide. Drug Deliv. 2013:1–20.
25. Vanlerberghe G, Handjani-Vila RM, Ribier A. Les niosomes, une nouvelle famille de vésicules à base d’amphiphiles non ioniques, Physicochimie des composés amphiphiles. Coll. Nat. 1978;303–11.
26. Handjani-Vila RM, Ribier A, Rondot A, Vanlerberghe G. Dispersions of lamellar phases of non- ionic lipids in cosmetic products. Int. J. Cosmetic Sci. 1979; 30314.
27. Baillie AJ, Coombs GH, Dolan TF, Laurie J. Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmannial drug, sodium stibogluconate. J. Pharm. Pharmacol. 1986; 38: 502–5.
28. Hamishehkar H, Rahimpour Y, Kouhsoltani M. Niosomes as a propitious carrier for topical drug delivery. Expert Opin Drug Deliv. 2013;10(2):261–72.
29. Van Abbe NJ. Development of effective ocular preparations of antifungal agents. J Soc Cosmet. Chem. 1973; 24: 685–7.
30. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta. 1991; 1066: 29–36.
31. Azeem A, Anwer MK, Talegaonkar S. Niosomes in sustained and targeted drug delivery: some recent advances. J Drug Target. 2009;17(9):671–89.
32. El-Ridy MS, Abdelbary A, Essam T, El-Salam RM, Kassem AA. Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin. Drug Dev Ind Pharm. 2011;37(12): 1491–508.
33. Di Turi G, Riggio C, Vittorio O, Marconcini S, Briguglio F, Funel N. Sub-micrometric liposomes as drug delivery systems in the treatment of periodontitis. Int J Immunopathol Pharmacol. 2012;25(3):657–70.
34. Jin HL, Wu W, Shu R. [Doxycycline nano-liposome slow-release gel improves rat periodontitis]. Shanghai Kou Qiang Yi Xue. 2010;19(5):508–11.
35. Petelin M, Pavlica Z, Ivanusa T, Sentjurc M, Skaleric U. Local delivery of liposome-encapsulated superoxide dismutase and catalase suppress periodontal inflammation in beagles. J Clin Periodontol. 2000;27(12):918–25.
36. Chen L, Chen C. Preparation and evaluation of semi-permanent hair dyes liposome. J Microencapsul. 2011;28(3):176–82.
37. Mao Y, Triantafillou G, Hertlein E, Towns W, Stefanovski M, Mo X. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies. Clin Cancer Res. 2013;19(2):347–56.
38. Zhou Q, Liu L, Zhang D, Fan X. Analysis of gemcitabine liposome injection by HPLC with evaporative light scattering detection. J Liposome Res. 2012;22(4):263–9.
39. Xiang Q, Xiao J, Zhang H, Zhang X, Lu M, Su Z. Preparation and characterisation of bFGF- encapsulated liposomes and evaluation of wound-healing activities in the rat. Burns. 2011;37(5):886–95.
40. de Carvalho Maroni L, de Oliveira Silveira AC, Leite EA, Melo MM, de Carvalho Ribeiro AF, Cassali GD. Antitumor effectiveness and toxicity of cisplatin-loaded long-circulating and pH-sensitive liposomes against Ehrlich ascitic tumor. Exp Biol Med (Maywood). 2012;237(8):973–84.
41. Ramana LN, Sharma S, Sethuraman S, Ranga U, Krishnan UM. Investigation on the stability of saquinavir loaded liposomes: implication on stealth, release characteristics and cytotoxicity. Int J Pharm. 2012,3210(115–2):120–9.
42. Shafaa MW, Sabra NM, Fouad RA. The extended ocular hypotensive effect of positive liposomal cholesterol bound timolol maleate in glaucomatous rabbits. Biopharm Drug Dispos. 2011;32(9): 507–17.
43. Zhang H, Wang ZY, Gong W, Li ZP, Mei XG, Lv WL. Development and characteristics of temperature-sensitive liposomes for vinorelbine bitartrate. Int J Pharm. 2011;414(1–2):56–62.
44. Walton BL, Leja M, Vickers KC, Estevez-Fernandez M, Sanguino A, Wang E. Delivery of negatively charged liposomes into the atheromas of Watanabe heritable hyperlipidemic rabbits. Vasc Med. 2010;15(4): 307–13.
45. Patel VB, Misra AN, Marfatia YS. Preparation and comparative clinical evaluation of liposomal gel of benzoyl peroxide for acne. Drug Dev Ind Pharm. 2001;27(8):863–9.
46. Honzak L, Sentjurc M. Development of liposome encapsulated clindamycin for treatment of acne vulgaris. Pflugers Arch. 2000;440(5 Suppl):R44–5.
47. Caddeo C, Teskac K, Sinico C, Kristl J. Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int J Pharm. 2008;363(1–2):183–91.
48. Baillie AJ, Coombs GH, Dolan TF, Laurie J. Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharm Pharmacol. 1986;38(7):502–5.
49. Parnami N, Garg T, Rath G, Goyal AK. Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. Artif Cells Nanomed Biotechnol. 2013;42(6); 406–12.
50. Dufes C, Schatzlein AG, Tetley L, Gray AI, Watson DG, Olivier JC. Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting. Pharm Res. 2000;17(10):1250–8.
51. Singh O, Garg T, Rath G, Goyal AK. Microbicides for the treatment of sexually transmitted hiv infections. J Pharmaceut. 2014:1–18.
52. Hashim F, El-Ridy M, Nasr M, Abdallah Y. Preparation and characterization of niosomes containing ribavirin for liver targeting. Drug Deliv. 2010;17(5):282–7.
53. Abdelkader H, Ismail S, Kamal A, Alany RG. Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery. J Pharm Sci. 2011;100(5):1833–46.
54. Singh K, Arora N, Garg T. Superbug: antimicrobial resistance due to NDM-1. Int J Inst Pharm Life Sci. 2012;2(2):58–66.
55. Cozar-Bernal MJ, Rabasco AM, Gonzalez-Rodriguez ML. Development and validation of a high performance chromatographic method for determining sumatriptan in niosomes. J Pharm Biomed Anal. 2013;72:251–60.
56. Mehta SK, Jindal N, Kaur G. Quantitative investigation, stability and in vitro release studies of anti-TB drugs in Triton niosomes. Colloids Surf B Biointerfaces. 2011;87(1):173–9.
57. Rajan R, Jose S, Mukund VP, Vasudevan DT. Transferosomes—a vesicular transdermal delivery system for enhanced drug permeation. J Adv Pharm Technol Res. 2011;2(3):138–43.
58. Singh K, Arora N, Garg T. RFID: a trustable security tool in pharmaceutical industry. Am J Pharm Tech Res. 2012;2(2):113–27.
59. D. Pando, G. Gutiérrez, J. Coca, Pazos C. Preparation and characterization of niosomes containing resveratrol. J Food Engineer. 2013;117(2):227–34.
60. Martin A, Pappas A, Lulic-Botica M, Natarajan G. Impact of ‘targeted’ fluconazole prophylaxis for preterm neonates: efficacy of a highly selective approach? J Perinatol. 2012;32(1):21–6.
61. Guinedi AS, Mortada ND, Mansour S, Hathout RM. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm. 2005;306(1–2):71–82.
62. Nagaraju R, Pallavi K, Deepthy K, Haritha M. Formulation and evaluation of niosomal nasal drug delivery system of folic acid for brain targeting. Curr Drug Discov Technol. 2013;10(4):270–82.
63. Prabhu P, Koland M, Vijaynarayan K, Harish N, Ganesh D, R C. Preparation and evaluation of Nio- somes of Brimonidine tartrate as ocular drug delivery system. Int J Pharmaceut Sci. 2010;2(4): 293–301.
64. Tavano L, Gentile L, Oliviero Rossi C, Muzzalupo R. Novel gel-niosomes formulations as multicomponent systems for transdermal drug delivery. Colloids Surf B Biointerfaces. 2013;110:281–8.
65. Hasan AA, Madkor H, Wageh S. Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system. Drug Deliv. 2013;20(3–4);120–6.
66. Vyas SP, Mysore N, Jaitely V, Venkatesan N. Discoidal niosome based controlled ocular delivery of timolol maleate. Pharmazie. 1998;53(7):466–9.
67. Marianecci C, Rinaldi F, Esposito S, Di Marzio L, Carafa M. Niosomes encapsulating Ibuprofencyclodextrin complexes: preparation and characterization. Curr Drug Targets. 2013;14(9):1070–8.
68. Manosroi J, Khositsuntiwong N, Manosroi W, Gotz F, Werner RG, Manosroi A. Potent enhancement of transdermal absorption and stability of human tyrosinase plasmid (pAH7/Tyr) by Tat peptide and an entrapment in elastic cationic niosomes. Drug Deliv. 2013;20(1):10–18.
69. Tavano L, Vivacqua M, Carito V, Muzzalupo R, Caroleo MC, Nicoletta F. Doxorubicin loaded magneto-niosomes for targeted drug delivery. Colloids Surf B Biointerfaces. 2013;102:803–7.
70. Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm. 2005;290(1–2):155–9.
71. Marianecci C, Rinaldi F, Mastriota M, Pieretti S, Trapasso E, Paolino D. Anti-inflammatory activity of novel ammonium glycyrrhizinate/niosomes delivery system: human and murine models. J Control Release. 2012;164(1):17–25.
72. Mehta SK, Jindal N. Formulation of Tyloxapol niosomes for encapsulation, stabilization and dissolution of anti-tubercular drugs. Colloids Surf B Biointerfaces. 2013;101:434–41.
73. Aggarwal D, Pal D, Mitra AK, Kaur IP. Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. Int J Pharm. 2007;338(1–2):21–6.
74. Patel RB, Parikh RH. Preparation and formulation of transferosomes containing an antifungal agent for transdermal delivery: Application of Plackett-Burman design to identify significant factors influencing vesicle size. J Pharm Bioallied Sci. 2012;4(Suppl 1):S60–1.
75. Alvi IA, Madan J, Kaushik D, Sardana S, Pandey RS, Ali A. Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in-vitro release, and cytotoxicity analysis. Anticancer Drugs. 2011;22(8):774–82.
76. Irfan M, Verma S, Ram A. Preparation and characterization of ibuprofen loaded transferosome as a novel carrier for transdermal drug delivery system. Asian J Pharmaceut Clin Res. 2012;5(3): 33–40.
77. Arunothayanun P, Uchegbu IF, Craig DQ, Turton JA, Florence AT. In vitro/in vivo characterisation of polyhedral niosomes. Int J Pharm. 1999;183(1):57–61.
78. Garg T, Rath G, Goyal AK. Comprehensive review on additives of topical dosage forms for drug delivery. Drug Deliv. 2014.
79. Bhalaria MK, Naik S, Misra AN. Ethosomes: a novel delivery system for antifungal drugs in the treatment of topical fungal diseases. Indian J Exp Biol. 2009;47(5):368–75.
80. Duangjit S, Opanasopit P, Rojanarata T, Ngawhirunpat T. Evaluation of meloxicam-loaded cationic transfersomes as transdermal drug delivery carriers. AAPS PharmSciTech. 2013;14(1):133–40.
81. Maurya SD, Aggarwal S, Tilak VK, Dhakar RC, Singh A, Maurya G. Enhanced transdermal delivery of indinavir sulfate via transfersomes. International journal of comprehensive pharmacy. 2012;1(1):1–10.
82. Scorneaux B, Lehmann J, Payne G, Cevc G, Rother M. transdermal delivery of interferon beta-1a by transfersomes and its effects on surrogate markers. Arch Neurol 2000;57(8):1239.
83. Ghanbarzadeh S, Arami S. Enhanced transdermal delivery of diclofenac sodium via conventional liposomes, ethosomes, and transfersomes. Biomed Res Int. 2013;2013:616810.
84. Patel R, Singh SK, Singh S, Sheth NR, Gendle R. Development and characterization of curcumin loaded transfersome for transdermal delivery. J Pharm Sci & Res. 2009;1(4):71–80.
85. WO Yan, Zhang Yi-Xin, Mao Xiao-Hui, Qian Yun-Liang, Wang Dan-Ru, HE Rong. Experimental study of transfersomes in hypertrophic scar penetration in vitro. J Shanghai Jiaotong Univ (Sci). 2011;45(6):929–34.
86. Ghannoum M, Isham N, Henry W, Kroon HA, Yurdakul S. Evaluation of the morphological effects of TDT 067 (terbinafine in transfersome) and conventional terbinafine on dermatophyte hyphae in vitro and in vivo. Antimicrob Agents Chemother. 2012;56(5):2530–4.
87. Gupta PN, Mishra V, Singh P, Rawat A, Dubey P, Mahor S. Tetanus toxoid-loaded transfersomes for topical immunization. J Pharm Pharmacol. 2005;57(3):295–301.
88. Boinpally RR, Zhou SL, Poondru S, Devraj G, Jasti BR. Lecithin vesicles for topical delivery of diclofenac. Eur J Pharm Biopharm. 2003;56(3):389–92.
89. Rother M, Lavins BJ, Kneer W, Lehnhardt K, Seidel EJ, Mazgareanu S. Efficacy and safety of epicuketoprofen Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial. Ann Rheum Dis. 2007;66(9):1178–83.
90. Singodia D, Gupta GK, Verma A, Singh V, Shukla P, Misra P. Development and performance evaluation of amphotericin B transfersomes against resistant and sensitive clinical isolates of visceral leishmaniasis. J Biomed Nanotechnol. 2010;6(3):293–302.
91. Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M, Ali A. Formulation and optimization of nanotransfersomes using experimental design technique for accentuated transdermal delivery of valsartan. Nanomedicine. 2012;8(2):237–49.
92. Simoes SI, Delgado TC, Lopes RM, Jesus S, Ferreira AA, Morais JA. Developments in the rat adjuvant arthritis model and its use in therapeutic evaluation of novel noninvasive treatment by SOD in Transfersomes. J Control Release. 2005;103(2):419–34.
93. Zheng WS, Fang XQ, Wang LL, Zhang YJ. Preparation and quality assessment of itraconazole transfersomes. Int J Pharm. 2012;436(1–2):291–8.
94. Barupal AK, Gupta V, Ramteke S. Preparation and characterization of ethosomes for topical delivery of aceclofenac. Indian J Pharm Sci. 2010;72(5):582–6.
95. Ainbinder D, Paolino D, Fresta M, Touitou E. Drug delivery applications with ethosomes. J Biomed Nanotechnol. 2010;6(5):558–68.
96. Cortesi R, Romagnoli R, Drechsler M, Menegatti E, Zaid AN, Ravani L. Liposome- and ethosomeassociated distamycins: a comparative study. J Liposome Res. 2010;20(4):277–85.
97. Celia C, Trapasso E, Cosco D, Paolino D, Fresta M. Turbiscan lab expert analysis of the stability of ethosomes and ultradeformable liposomes containing a bilayer fluidizing agent. Colloids Surf B Biointerfaces. 2009;72(1):155–60.
98. Garg G, Saraf S. Cubosomes: an overview. Biol Pharm Bull. 2007;30(2):350–3.
99. Yang D, O’Brien DF, Marder SR. Polymerized bicontinuous cubic nanoparticles (cubosomes) from a reactive monoacylglycerol. J Am Chem Soc. 2002;124(45):13388–9.
100. Shen HH, Lake V, Le Brun AP, James M, Duff AP, Peng Y. Targeted detection of phosphatidylserine in biomimetic membranes and in vitro cell systems using annexin V-containing cubosomes. Biomaterials. 2013;34(33):8361–9.
101. Mao YT, Hua HY, Zhang XG, Zhu DX, Li F, Gui ZH. Ethosomes as delivery system for transdermal administration of vinpocetine. Pharmazie. 2013;68(5):381–2.
102. Na B, Choi BW, Kim B. Size and CT density of iodine-containing ethosomal vesicles obtained by membrane extrusion: potential for use as CT contrast agents. Biotechnol J. 2013;8(11):1347–53.
103. Rakesh R, Anoop KR. Formulation and optimization of nano-sized ethosomes for enhanced transdermal delivery of cromolyn sodium. J Pharm Bioallied Sci. 2012;4(4):333–40.
104. Zhao YZ, Lu CT, Zhang Y, Xiao J, Zhao YP, Tian JL. Selection of highly efficient transdermal lipid vesicle for curcumin skin delivery. Int J Pharm. 2013;454(1):302–9.
105. Ascenso A, Pinho S, Eleuterio C, Praca FG, Bentley MV, Oliveira H. Lycopene from tomatoes: vesicular nanocarrier formulations for dermal delivery. J Agric Food Chem. 2013;61(30):7284–93.
106. Zhu X, Li F, Peng X, Zeng K. Formulation and evaluation of lidocaine base ethosomes for transdermal delivery. Anesth Analg. 2013;117(2):352–7.
107. Sarwa KK, Suresh PK, Debnath M, Ahmad MZ. Tamoxifen citrate loaded ethosomes for transdermal drug delivery system: preparation and characterization. Curr Drug Deliv. 2013;10(4):466–76.
108. Yeh MI, Huang HC, Liaw JH, Huang MC, Wu TH, Huang KF. Ethosomes in hair dye products as carriers of the major compounds of black tea extracts. Int J Dermatol. 2013;52(7):868–75.
109. Mishra AD, Patel CN, Shah DR. Formulation and optimization of ethosomes for transdermal delivery of ropinirole hydrochloride. Curr Drug Deliv. 2013.
110. Li C, Deng L, Zhang Y, Su TT, Jiang Y, Chen ZB. [Silica-coated ethosome as a novel oral delivery system for enhanced oral bioavailability of curcumin]. Yao Xue Xue Bao. 2012;47(11):1541–7.
111. Bhosale SS, Avachat AM. Design and development of ethosomal transdermal drug delivery system of valsartan with preclinical assessment in Wistar albino rats. J Liposome Res. 2013;23(2):119–25.
112. Bodade SS, Shaikh KS, Kamble MS, Chaudhari PD. A study on ethosomes as mode for transdermal delivery of an antidiabetic drug. Drug Deliv. 2013;20(1):40–6.
113. Yang X, Ao H, Cheng X, Gu J, Kong D, Mao X. [Preparation of ethosomes encapsulated with 5-fluorouracil and the effect of local administered 5-FU ethosome on laryngotracheal stenosis of rabbit]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012;26(20):939–43.
114. Cortesi R, Ravani L, Menegatti E, Drechsler M, Esposito E. Colloidal dispersions for the delivery of acyclovir: a comparative study. Indian J Pharm Sci. 2011;73(6):687–93.
115. Uyama M, Nakano M, Yamashita J, Handa T. Useful modified cellulose polymers as new emulsifiers of cubosomes. Langmuir. 2009;25(8):4336–8.
116. Rattanapak T, Young K, Rades T, Hook S. Comparative study of liposomes, transfersomes, ethosomes and cubosomes for transcutaneous immunisation: characterisation and in vitro skin penetration. J Pharm Pharmacol. 2012;64(11):1560–9.
117. Moser C, Muller M, Kaeser MD, Weydemann U, Amacker M. Influenza virosomes as vaccine adjuvant and carrier system. Expert Rev Vaccines. 2013;12(7):779–91.
118. Zurbriggen R. Immunostimulating reconstituted influenza virosomes. Vaccine. 2003;21(9–10): 921–4.
119. Cusi MG, Zurbriggen R, Correale P, Valassina M, Terrosi C, Pergola L. Influenza virosomes are an ef ficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity. Vaccine. 2002;20(29–30):3436–42.
120. Khoshnejad M, Young PR, Toth I, Minchin RF. Modified influenza virosomes: recent advances and potential in gene delivery. Curr Med Chem. 2007;14(29):3152–6.
121. Morsi NM, Abdelbary GA, Ahmed MA. Silver sulfadiazine based cubosome hydrogels for topical treatment of burns: Development and in vitro/in vivo characterization. Eur J Pharm Biopharm. 2013;86(2):178–89.
122. Rizwan SB, McBurney WT, Young K, Hanley T, Boyd BJ, Rades T. Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses. J Control Release. 2013;165(1):16–21.
123. Murgia S, Bonacchi S, Falchi AM, Lampis S, Lippolis V, Meli V. Drug-loaded fluorescent cubosomes: versatile nanoparticles for potential theranostic applications. Langmuir. 2013;29(22):6673–9.
124. Yang Z, Tan Y, Chen M, Dian L, Shan Z, Peng X. Development of amphotericin B-loaded cubosomes through the SolEmuls technology for enhancing the oral bioavailability. AAPS PharmSciTech. 2012;13(4):1483–91.
125. Bei D, Zhang T, Murowchick JB, Youan BB. Formulation of dacarbazine-loaded cubo-somes. Part III. Physicochemical characterization. AAPS PharmSciTech. 2010;11(3):1243–9.
126. Han S, Shen JQ, Gan Y, Geng HM, Zhang XX, Zhu CL. Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacol Sin. 2010;31(8):990–8.
127. Efrat R, Kesselman E, Aserin A, Garti N, Danino D. Solubilization of hydrophobic guest molecules in the monoolein discontinuous QL cubic mesophase and its soft nanoparticles. Langmuir. 2009;25(3):1316–26.
128. Gordon S, Young K, Wilson R, Rizwan S, Kemp R, Rades T. Chitosan hydrogels containing lipo-somes and cubosomes as particulate sustained release vaccine delivery systems. J Liposome Res. 2012;22(3):193–204.
129. Wu H, Li J, Zhang Q, Yan X, Guo L, Gao X. A novel small Odorranalectin-bearing cubo-somes: preparation, brain delivery and pharmacodynamic study on amyloid-beta(2)(5)(-)(3)(5)-treated rats following intranasal administration. Eur J Pharm Biopharm. 2012;80(2):368–78.
130. Kojarunchitt T, Hook S, Rizwan S, Rades T, Baldursdottir S. Development and characterization of modified poloxamer 407 thermoresponsive depot systems containing cubosomes. Int J Pharm. 2011;408(1–2):20–6.
131. Rizwan SB, Assmus D, Boehnke A, Hanley T, Boyd BJ, Rades T. Preparation of phytantriol cubosomes by solvent precursor dilution for the delivery of protein vaccines. Eur J Pharm Biopharm. 2011;79(1):15–22.
132. Nguyen TH, Hanley T, Porter CJ, Boyd BJ. Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration. J Control Release. 2011;153(2):180–6.
133. Gan L, Han S, Shen J, Zhu J, Zhu C, Zhang X. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: improving preocular retention and ocular bioavailability. Int J Pharm. 2010;396(1–2):179–87.
134. Lai J, Lu Y, Yin Z, Hu F, Wu W. Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. Int J Nanomedicine. 2010;5:13–23.
135. Yashmur A, Laggner P, Almgren M, Rappolt M. Self-assembly in monoelaidin aqueous dispersions: direct vesicles to cubosomes transition. PLoS One. 2008;3(11):e3747.
136. Gluck R, Burri KG, Metcalfe I. Adjuvant and antigen delivery properties of virosomes. Curr Drug Deliv. 2005;2(4):395–400.
137. Bombardelli E. Phytosome: new cosmetic delivery system. Boll Chim Farm. 1991;130(11):431–8.
138. Di Pierro F, Menghi AB, Barreca A, Lucarelli M, Calandrelli A. Greenselect Phytosome as an adjunct to a low-calorie diet for treatment of obesity: a clinical trial. Altern Med Rev. 2009;14(2):154–60.
139. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 2007;25(2):139–46.
140. Magrone T, Pugliese V, Fontana S, Jirillo E. Human use of leucoselect phytosome with special reference to inflammatory-allergic pathologies in frail elderly patients. Curr Pharm Des. 2013;20(6): 1011–9.
141. Danielsson I, Lindman B. The definition of microemulsion. Colloids Surf. 1981;3:391–2.
142. Entezari MH, Ghows N. Micro-emulsion under ultrasound facilitates the fast synthesis of quantum dots of CdS at low temperature. Ultrason Sonochem. 2011;18(1):127–34.
143. Abdoli A, Soleimanjahi H, Kheiri MT, Jamali A, Sohani H, Abdoli M. Reconstruction of H3N2 influenza virus based virosome in-vitro. Iran J Microbiol. 2013;5(2):166–71.
144. Shafique M, Meijerhof T, Wilschut J, de Haan A. Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses. PLoS One. 2013;8(4):e61287.
145. Kamphuis T, Stegmann T, Meijerhof T, Wilschut J, de Haan A. A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats. Influenza Other Resp Virus. 2013;7(6):1227–36.
146. Kamphuis T, Shafique M, Meijerhof T, Stegmann T, Wilschut J, de Haan A. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats. Vaccine. 2013;31(17):2169–76.
147. Jamali A, Holtrop M, de Haan A, Hashemi H, Shenagari M, Memarnejadian A. Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination. Immunol Lett. 2012;148(1):77–82.
148. Mallick AI, Kulkarni RR, St Paul M, Parvizi P, Nagy E, Behboudi S. Vaccination with CpG-adjuvanted avian influenza virosomes promotes antiviral immune responses and reduces virus shedding in chickens. Viral Immunol. 2012;25(3):226–31.
149. De Bernardis F, Amacker M, Arancia S, Sandini S, Gremion C, Zurbriggen R. A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models. Vaccine. 2012;30(30):4490–8.
150. Huckriede A, De Jonge J, Holtrop M, Wilschut J. Cellular delivery of siRNA mediated by fusionactive virosomes. J Liposome Res. 2007;17(1):39–47.
151. Pedersen GK, Ebensen T, Gjeraker IH, Svindland S, Bredholt G, Guzman CA. Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS One. 2011;6(11):e26973.
152. Natilla A, Hammond RW. Maize rayado fino virus virus-like particles expressed in tobacco plants: a new platform for cysteine selective bioconjugation peptide display. J Virol Methods. 2011;178(1–2):209–15.
153. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity. 2011;34(2):269–80.
154. Gandhi KM, Mandrell RE, Tian P. Binding of virus-like particles of Norwalk virus to romaine lettuce veins. Appl Environ Microbiol. 2010;76(24):7997–8003.
155. Yun SI, Song BH, Koo Y, Jeon I, Byun SJ, Park JH. Japanese encephalitis virus-based replicon RNAs/ particles as an expression system for HIV-1 Pr55 Gag that is capable of producing virus-like particles. Virus Res. 2009;144(1–2):298–305.
156. Subramanian N, Mani P, Roy S, Gnanasundram SV, Sarkar DP, Das S. Targeted delivery of hepatitis C virus-specific short hairpin RNA in mouse liver using Sendai virosomes. J Gen Virol. 2009;90(Pt8):1812–9.
157. de Jonge J, Leenhouts JM, Holtrop M, Schoen P, Scherrer P, Cullis PR. Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA. Biochem J. 2007;405(1):41–9.
158. Arleth L, Svensson B, Mortensen K, Pedersen JS, Olsson U. Block-copolymer micro- emulsion with solvent-induced segregation. Langmuir. 2007;23(4):2117–25.
159. Trotta M, Cavalli R, Carlotti ME, Battaglia L, Debernardi F. Solid lipid micro-particles carrying insulin formed by solvent-in-water emulsion-diffusion technique. Int J Pharm. 2005;288(2):281–8.
160. Shipovskov S, Oliveira CL, Hoffmann SV, Schauser L, Sutherland DS, Besenbacher F. Water-inoil micro-emulsion enhances the secondary structure of a protein by confinement. Chemphyschem. 2012;13(13):3179–84.
161. Besnard L, Marchal F, Paredes JF, Daillant J, Pantoustier N, Perrin P. Multiple emulsions controlled by stimuli-responsive polymers. Adv Mater. 2013;25(20):2844–8.
162. Khan AY, Talegaonkar S, Iqbal Z, Ahmed FJ, Khar RK. Multiple emulsions: an overview. Curr Drug Deliv. 2006;3(4):429–43.
163. Freag MS, Elnaggar YS, Abdallah OY. Lyophilized phytosomal nanocarriers as platforms for enhanced diosmin delivery: optimization and ex vivo permeation. Int J Nanomedicine. 2013;8:2385–97.
164. Hou Z, Li Y, Huang Y, Zhou C, Lin J, Wang Y. Phytosomes loaded with mitomycin C-soybean phosphatidylcholine complex developed for drug delivery. Mol Pharm. 2013;10(1):90–101.
165. Ma YQ, Li G, Xu JH, Zhang J, Zhang ZZ, Xiao HY. Combination of submicroemulsion and phospholipid complex for novel delivery of ursodeoxycholic acid. Pharm Dev Technol. 2013;19(3):363–72.
166. Javed S, Kohli K, Ali M. Reassessing bioavailability of silymarin. Altern Med Rev. 2011;16(3): 239–49.
167. Zhang J, Tang Q, Xu X, Li N. Development and evaluation of a novel phytosome-loaded chitosan microsphere system for curcumin delivery. Int J Pharm. 2013;448(1):168–74.
168. Sharma A, Gupta NK, Dixit VK. Complexation with phosphatidyl choline as a strategy for absorption enhancement of boswellic acid. Drug Deliv. 2010;17(8):587–95.
169. Jiang YN, Mo HY, Chen JM. [Effects of epimedium total flavonoids phytosomes on preventing and treating bone-loss of ovariectomized rats]. Zhongguo Zhong Yao Za Zhi. 2002;27(3):221–4.
170. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev. 2009;14(3):226–46.
171. Panda VS, Naik SR. Cardioprotective activity of Ginkgo biloba phytosomes in isoproterenol-induced myocardial necrosis in rats: a biochemical and histoarchitectural evaluation. Exp Toxicol Pathol. 2008;60(4–5):397–404.
172. Naik SR, Panda VS. Antioxidant and hepatoprotective effects of Ginkgo biloba phytosomes in carbon tetrachloride-induced liver injury in rodents. Liver Int. 2007;27(3):393–9.
173. Naik SR, Pilgaonkar VW, Panda VS. Evaluation of antioxidant activity of Ginkgo biloba phytosomes in rat brain. Phytother Res. 2006;20(11):1013–6.
174. Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phyto-some: a silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev. 2005;10(3):193–203.
175. Naik SR, Pilgaonkar VW, Panda VS. Neuropharmacological evaluation of Ginkgo biloba phytosomes in rodents. Phytother Res. 2006;20(10):901–5.
176. Jiang YN, Yu ZP, Yang ZM, Chen JM. [Studies on preparation of herba epimedii total fla-vonoids phytosomes and their pharmaceutics]. Zhongguo Zhong Yao Za Zhi. 2001;26(2):105–8.
177. El-Gazayerly ON, Makhlouf AI, Soelm AM, Mohmoud MA. Antioxidant and hepatoprotective effects of silymarin phytosomes compared to milk thistle extract in CCl induced hepatotoxicity in rats. J Microencapsul. 2013.
178. Chen AZ, Yang YM, Wang SB, Wang GY, Liu YG, Sun QQ. Preparation of methotrexate-loaded, large, highly-porous PLLA microspheres by a high-voltage electrostatic antisolvent process. J Mater Sci Mater Med. 2013;24(8):1917–25.
179. Himes R, Lee S, McMenigall K, Russell-Jones GJ. Reduction in inflammation in the footpad of carrageenan treated mice following the topical administration of anti-TNF molecules formulated in a micro-emulsion. J Control Release. 2010;145(3):210–3.
180. Abdullah GZ, Abdulkarim MF, Mallikarjun C, Mahdi ES, Basri M, Sattar MA. Carbopol 934, 940 and Ultrez 10 as viscosity modifiers of palm olein esters based nano-scaled emulsion containing ibuprofen. Pak J Pharm Sci. 2013;26(1):75–83.
181. Hoeller S, Kahlig H, Valenta C. Multinuclear NMR characterisation and dermal delivery of fluorinated drugs in soybean-microemulsion systems. J Pharm Sci. 2009;98(8):2686–95.
182. Jin S, Feng L, Yu X. Preparation and characterization of aspirin/chitosan nanoparticles by nucleation and ionic crosslinking in micro emulsions. J Control Release. 2011;152(Suppl 1):e39–41.
183. Wu X, Wei X, Gu C, Chen Y, Wu H, Zhang J. Optimisation of Dex-GMA nanoparticles prepared in modified micro-emulsion system: physical and biologic characterization. J Biotechnol. 2009;143(4):268–73.
184. Mohagheghpour E, Moztarzadeh F, Rabiee M, Tahriri M, Ashuri M, Sameie H. Micro-emulsion synthesis, surface modification, and photophysical properties of Zn(1-x) Mn(x)S nanocrystals for biomolecular recognition. IEEE Trans Nanobiosci. 2012;11(4):317–23.
185. Jeong CW, Ju J, Lee DW, Lee SH, Yoon MH. Lipid-emulsion propofol less attenuates the regulation of body temperature than micro-emulsion propofol or sevoflurane in the elderly. Yonsei Med J. 2012;53(1):198–203.
186. Mei Z, Chen H, Weng T, Yang Y, Yang X. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur J Pharm Biopharm. 2003;56(2):189–96.
187. Shinde U, Pokharkar S, Modani S. Design and evaluation of microemulsion gel system of nadifloxacin. Indian J Pharm Sci. 2012;74(3):237–47.
188. Li P, Hynes SR, Haefele TF, Pudipeddi M, Royce AE, Serajuddin AT. Development of clinical dosage forms for a poorly water-soluble drug II: formulation and characterization of a novel solid microemulsion preconcentrate system for oral delivery of a poorly water-soluble drug. J Pharm Sci. 2009;98(5):1750–64.
189. Gupta S, Sanyal SK, Datta S, Moulik SP. Preparation of prospective plant oil derived micro-emulsion vehicles for drug delivery. Indian J Biochem Biophys. 2006;43(4):254–7.
190. Theilen HJ, Adam S, Albrecht MD, Ragaller M. Propofol in a medium- and long-chain triglyceride emulsion: pharmacological characteristics and potential beneficial effects. Anesth Analg. 2002;95(4):923–9
191. Cirri M, Mura P, Mora PC. Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems. Int J Pharm. 2007;340(1–2):84–91.
192. Szucs M, Sandri G, Bonferoni MC, Caramella CM, Vaghi P, Szabo-Revesz P. Mucoadhesive behavior of emulsions containing polymeric emulsifier. Eur J Pharm Sci. 2008;34(4–5):226–35.
193. de Luca M, Grossiord JL, Seiller M. A very stable W/O/W multiple emulsion. Int J Cosmet Sci. 2000;22(2):157–61.
194. Fattal E, Roques B, Puisieux F, Blanco-Prieto MJ, Couvreur P. Multiple emulsion technology for the design of microspheres containing peptides and oligopeptides. Adv Drug Deliv Rev. 1997;28(1):85–96.
195. Singh S, Singh R, Vyas SP. Multiple emulsion-based systems carrying insulin: development and characterization. J Microencapsul. 1995;12(6):609–15.
196. Chahibi Y, Pierobon M, Song SO, Akyildiz I. A Molecular Communication System Model for Particulate Drug Delivery Systems. IEEE Trans Biomed Eng. 2013;2:23–33.
197. Zhang Y, Chan HF, Leong KW. Advanced materials and processing for drug delivery: the past and the future. Adv Drug Deliv Rev. 2013;65(1):104–20.
198. Serrano-Ruiz D, Laurenti M, Ruiz-Cabello J, Lopez-Cabarcos E, Rubio-Retama J. Hybrid microparticles for drug delivery and magnetic resonance imaging. J Biomed Mater Res B Appl Biomater. 2013;101(4):498–505.
199. Xie J, Marijnissen JC, Wang CH. Microparticles developed by electrohydrodynamic atomization for the local delivery of anticancer drug to treat C6 glioma in vitro. Biomaterials. 2006;27(17):3321–32.
200. Paul S, Kumar A, Yedurkar P, Sawant K. Design and development of multiple emulsion for enhancement of oral bioavailability of acyclovir. Drug Dev Ind Pharm. 2013;39(11):1809–17.
201. Tang SY, Sivakumar M, Ng AM, Shridharan P. Anti-inflammatory and analgesic activity of novel oral aspirin-loaded nanoemulsion and nano multiple emulsion formulations generated using ultrasound cavitation. Int J Pharm. 2012;430(1–2):299–306.
202. Schwarz JC, Klang V, Karall S, Mahrhauser D, Resch GP, Valenta C. Optimisation of multiple W/O/W nanoemulsions for dermal delivery of aciclovir. Int J Pharm. 2012;435(1):69–75.
203. Piacentini E, Drioli E, Giorno L. Preparation of stimulus responsive multiple emulsions by membrane emulsification using con a as biochemical sensor. Biotechnol Bioeng. 2011;108(4):913–23.
204. Doucet O, Ferrero L, Garcia N, Zastrow L. O/W emulsion and W/O/W multiple emulsion: physical characterization and skin pharmacokinetic comparison in the delivery process of caffeine. Int J Cosmet Sci. 1998;20(5):283–95.
205. Ozer O, Ozyazici M, Tedajo M, Taner MS, Koseoglu K. W/O/W multiple emulsions containing nitroimidazole derivates for vaginal delivery. Drug Deliv. 2007;14(3):139–45.
206. Tedajo GM, Bouttier S, Fourniat J, Grossiord JL, Marty JP, Seiller M. Release of antiseptics from the aqueous compartments of a w/o/w multiple emulsion. Int J Pharm. 2005;288(1):63–72.
207. Schmidts T, Dobler D, Schlupp P, Nissing C, Garn H, Runkel F. Development of multiple W/O/W emulsions as dermal carrier system for oligonucleotides: effect of additives on emulsion stability. Int J Pharm. 2010;398(1–2):107–13.
208. Learoyd TP, Burrows JL, French E, Seville PC. Sustained delivery of salbutamol and beclometasone from spray-dried double emulsions. J Microencapsul. 2010;27(2):162–70.
209. Shahiwala A, Amiji MM. Enhanced mucosal and systemic immune response with squalane oilcontaining multiple emulsions upon intranasal and oral administration in mice. J Drug Target. 2008;16(4):302–10.
210. Farahmand S, Tajerzadeh H, Farboud ES. Formulation and evaluation of a vitamin C multiple emulsion. Pharm Dev Technol. 2006;11(2):255–61.
211. Vasiljevic D, Parojcic J, Primorac M, Vuleta G. An investigation into the characteristics and drug release properties of multiple W/O/W emulsion systems containing low concentration of lipophilic polymeric emulsifier. Int J Pharm. 2006;309(1–2):171–7.
212. Talegaonkar S, Vyas SP. Inverse targeting of diclofenac sodium to reticuloendothelial system-rich organs by sphere-in-oil-in-water (s/o/w) multiple emulsion containing poloxamer 403. J Drug Target. 2005;13(3):173–8.
213. Bozkir A, Hayta G. Preparation and evaluation of multiple emulsions water-in-oil-in-water (w/o/w) as delivery system for influenza virus antigens. J Drug Target. 2004;12(3):157–64.
214. Onuki Y, Morishita M, Takayama K. Formulation optimization of water-in-oil-water multiple emulsion for intestinal insulin delivery. J Control Release. 2004;97(1):91–9.
215. Coombes AG, Tasker S, Lindblad M, Holmgren J, Hoste K, Toncheva V. Biodegradable polymeric microparticles for drug delivery and vaccine formulation: the surface attachment of hydrophilic species using the concept of poly(ethylene glycol) anchoring segments. Biomaterials. 1997;18(17):1153–61.
216. Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev. 2011;63(6):470–91.
217. Qutachi O, Shakesheff KM, Buttery LD. Delivery of definable number of drug or growth factor loaded poly(DL-lactic acid-co-glycolic acid) microparticles within human embryonic stem cell derived aggregates. J Control Release. 2013;168(1):18–27.
218. Kaur M, Malik B, Garg T, Rath G, Goyal AK. Development and characterization of guar gum nanoparticles for oral immunization against tuberculosis. Drug Deliv. 2014:1–12.
219. Couvreur P, Kante B, Grislain L, Roland M, Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles II. Doxorubicin-loaded nanoparticles. J. Pharm. Sci. 1982; 71:790–2.
220. Coaker H. Improved drug-delivery nanoparticles penetrate brain. Future Med Chem. 2012;4(17): 2135.
221. Couvreur P. Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev. 2013;65(1):21–3.
222. Eidi H, Joubert O, Nemos C, Grandemange S, Mograbi B, Foliguet B. Drug delivery by polymeric nanoparticles induces autophagy in macrophages. Int J Pharm. 2012;422(1–2):495–503.
223. Kadam RS, Bourne DW, Kompella UB. Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance. Drug Metab Dispos. 2012;40(7):1380–8.
224. Garg T, Goyal AK. Iontophoresis: Drug delivery system by applying an electrical potential across the skin. Drug Deliv Letts. 2012;2(4):270–80.
225. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine. 2012;8(2):147–66.
226. Kataria K, Sharma A, Garg T, Goyal AK, Rath G. Novel technology to improve drug loading in polymeric nanofibers. Drug Deliv Letts. 2014;4(1):79–86.
227. Paulis LE, Geelen T, Kuhlmann MT, Coolen BF, Schafers M, Nicolay K. Distribution of lipid-based nanoparticles to infarcted myocardium with potential application for MRI-monitored drug delivery. J Control Release. 2012;162(2):276–85.
228. Wolinsky JB, Colson YL, Grinstaff MW. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J Control Release. 2012;159(1):14–26.
229. Manca ML, Cassano R, Valenti D, Trombino S, Ferrarelli T, Picci N. Isoniazid-gelatin conjugate microparticles containing rifampicin for the treatment of tuberculosis. J Pharm Pharmacol. 2013;65(9):1302–11.
230. Chen F, Wu Z, Wang Q, Wu H, Zhang Y, Nie X. Preparation and biological characteristics of recombinant human bone morphogenetic protein-2-loaded dextran-co-gelatin hydrogel microspheres, in vitro and in vivo studies. Pharmacology. 2005;75(3):133–44.
231. Chen FM, Zhao YM, Wu H, Deng ZH, Wang QT, Zhou W. Enhancement of periodontal tissue regeneration by locally controlled delivery of insulin-like growth factor-I from dextran-co-gelatin microspheres. J Control Release. 2006;114(2):209–22.
232. Du C, Shi J, Zhang L, Cao S. PUA/PSS multilayer coated CaCO3 microparticles as smart drug delivery vehicles. Mater Sci Eng C Mater Biol Appl. 2013;33(7):3745–52.
233. Balabushevich NG, Pechenkin MA, Shibanova ED, Volodkin DV, Mikhalchik EV. Multi-functional polyelectrolyte microparticles for oral insulin delivery. Macromol Biosci. 2013;13(10):1379–88.
234. Regnier-Delplace C, Thillaye du Boullay O, Siepmann F, Martin-Vaca B, Degrave N, Demonchaux P. PLGA microparticles with zero-order release of the labile anti-Parkinson drug apomorphine. Int J Pharm. 2013;443(1–2):68–79.
235. Saraiva J, Lira AA, Esperandim VR, da Silva Ferreira D, Ferraudo AS, Bastos JK. (-)-Hinokininloaded poly(D,-lactide-co-glycolide) microparticles for Chagas disease. Parasitol Res. 2010;106(3): 703–8.
236. Yue IC, Poff J, Cortes ME, Sinisterra RD, Faris CB, Hildgen P. A novel polymeric chlorhexidine delivery device for the treatment of periodontal disease. Biomaterials. 2004;25(17):3743–50.
237. Liu DZ, Chen WP, Lee CP, Wu SL, Wang YC, Chung TW. Effects of alginate coated on PLGA microspheres for delivery tetracycline hydrochloride to periodontal pockets. J Microencapsul. 2004;21(6):643–52.
238. Mundargi RC, Srirangarajan S, Agnihotri SA, Patil SA, Ravindra S, Setty SB. Development and evaluation of novel biodegradable microspheres based on poly(d,l-lactide-co-glycolide) and poly(epsilon-caprolactone) for controlled delivery of doxycycline in the treatment of human periodontal pocket: in vitro and in vivo studies. J Control Release. 2007;119(1):59–68.
239. Rodriguez M, Antunez JA, Taboada C, Seijo B, Torres D. Colon-specific delivery of budesonide from microencapsulated cellulosic cores: evaluation of the efficacy against colonic inflammation in rats. J Pharm Pharmacol. 2001;53(9):1207–15.
240. de Sousa FO, Blanco-Mendez J, Perez-Estevez A, Seoane-Prado R, Luzardo-Alvarez A. Effect of zein on biodegradable inserts for the delivery of tetracycline within periodontal pockets. J Biomater Appl. 2012;27(2):187–200.
241. Park YJ, Lee JY, Yeom HR, Kim KH, Lee SC, Shim IK. Injectable polysaccharide microcapsu- les for prolonged release of minocycline for the treatment of periodontitis. Biotechnol Lett. 2005;27(22):1761–6.
242. Sendil D, Gursel I, Wise DL, Hasirci V. Antibiotic release from biodegradable PHBV microparticles. J Control Release. 1999;59(2):207–17.
243. Govender S, Lutchman D, Pillay V, Chetty DJ, Govender T. Enhancing drug incorporation into tetra cycline-loaded chitosan microspheres for periodontal therapy. J Microencapsul. 2006;23(7):750–61.
244. Garg T, Singh S, Goyal AK. Stimuli-sensitive hydrogels: an excellent carrier for drug and cell delivery. Crit Rev Ther Drug Carrier Syst. 2013;30(5):369–409.
245. Sultana S, Khan MR, Kumar M, Kumar S, Ali M. Nanoparticles-mediated drug delivery approaches for cancer targeting: a review. J Drug Target. 2013;21(2):107–25.
246. Garg T. Current nanotechnological approaches for an effective delivery of bio-active drug molecules in the treatment of acne. Artif Cells Nanomed Biotechnol. 2014:1–8.
247. Garg T, Goyal AK, Arora S, Murthy R. Development, optimization & evaluation of porous chitosan scaffold formulation of gliclazide for the treatment of type-2 diabetes mellitus. Drug Deliv Letts. 2012;2(4):251–61.
248. Zeng N, Gao X, Hu Q, Song Q, Xia H, Liu Z. Lipid-based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly water-soluble drugs: cellular interaction and in vivo absorption. Int J Nanomedicine. 2012;7:3703–18.
249. Kaur R, Garg T, Malik B, Gupta UD, Gupta P, Rath G. Development and characterization of spraydried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs. Drug Deliv. 2014:1–6.
250. Li W, Yang Y, Wang C, Liu Z, Zhang X, An F. Carrier-free, functionalized drug nanoparticles for targeted drug delivery. Chem Commun (Camb). 2012;48(65):8120–2.
251. Bamrungsap S, Zhao Z, Chen T, Wang L, Li C, Fu T. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine (Lond). 2012;7(8):1253–71.
252. Nasr M, Mansour S, Mortada ND, El Shamy AA. Lipospheres as carriers for topical delivery of aceclofenac: preparation, characterization and in vivo evaluation. AAPS PharmSciTech. 2008;9(1): 154–62.
253. Pardeshi CV, Belgamwar VS, Tekade AR, Surana SJ. Novel surface modified polymer-lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation. J Mater Sci Mater Med. 2013.
254. Yun X, Maximov VD, Yu J, Zhu H, Vertegel AA, Kindy MS. Nanoparticles for targeted delivery of antioxidant enzymes to the brain after cerebral ischemia and reperfusion injury. J Cereb Blood Flow Metab. 2013;33(4):583–92.
255. Costa Lima SA, Resende M, Silvestre R, Tavares J, Ouaissi A, Lin PK. Characterization and evaluation of BNIPDaoct-loaded PLGA nanoparticles for visceral leishmaniasis: in vitro and in vivo studies. Nanomedicine (Lond). 2012;7(12):1839–49.
256. Carroll RT, Bhatia D, Geldenhuys W, Bhatia R, Miladore N, Bishayee A. Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders. J Drug Target. 2010;18(9):665–74.
257. Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother. 2004;54(4):761–6.
258. Klepac-Ceraj V, Patel N, Song X, Holewa C, Patel C, Kent R. Photodynamic effects of methylene blue-loaded polymeric nanoparticles on dental plaque bacteria. Lasers Surg Med. 2011;43(7):600–6.
259. Durand R, Paul M, Rivollet D, Fessi H, Houin R, Astier A. Activity of pentamidine-loaded poly (D,Llactide) nanoparticles against Leishmania infantum in a murine model. Parasite. 1997;4(4):331–6.
260. Misra R, Sahoo SK. Antibacterial activity of doxycycline-loaded nanoparticles. Methods Enzymol. 2012;509:61–85.
261. Chopra A. Trastuzumab-dextran iron oxide nanoparticles. Molecular Imaging and Contrast Agent Database (MICAD). Bethesda, MD; 2004.
262. Al-Ghananeem AM, Saeed H, Florence R, Yokel RA, Malkawi AH. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses. J Drug Target. 2010;18(5):381–8.
263. Ambruosi A, Gelperina S, Khalansky A, Tanski S, Theisen A, Kreuter J. Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model. J Microencapsul. 2006;23(5):582–92.
264. Sakai T, Kohno H, Ishihara T, Higaki M, Saito S, Matsushima M. Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. Exp Eye Res. 2006;82(4):657–63.
265. Saboktakin MR, Tabatabaie RM, Maharramov A, Ramazanov MA. Development and in vitro evaluation of thiolated chitosan—poly(methacrylic acid) nanoparticles as a local mucoadhesive delivery system. Int J Biol Macromol. 2011;48(3):403–7.
266. Pinon-Segundo E, Ganem-Quintanar A, Alonso-Perez V, Quintanar-Guerrero D. Preparation and cha- racterization of triclosan nanoparticles for periodontal treatment. Int J Pharm. 2005;294(1–2): 217–32.
267. Fusai T, Deniau M, Durand R, Bories C, Paul M, Rivollet D. Action of pentamidine-bound nanoparticles against Leishmania on an in vivo model. Parasite. 1994;1(4):319–24.
268. Elgart A, Cherniakov I, Aldouby Y, Domb AJ, Hoffman A. Lipospheres and pro-nano lipospheres for delivery of poorly water soluble compounds. Chem Phys Lipids. 2012;165(4):438–53.
269. Cortesi R, Esposjto E, Luca G, Nastruzzi C. Production of lipospheres as carriers for bioactive compounds. Biomaterials. 2002;23(11):2283–94.
270. Natarajan SB, Lakshmanan P. Effect of Processing variables on characterization of ofloxacin loaded lipospheres prepared by melt dispersion technique. Curr Drug Deliv. 2012;10(5):517–26.
271. Iannuccelli V, Coppi G, Sergi S, Mezzena M, Scalia S. In vivo and in vitro skin permeation of butyl methoxydibenzoylmethane from lipospheres. Skin Pharmacol Physiol. 2008;21(1):30–8.
272. Valerii MC, Benaglia M, Caggiano C, Papi A, Strillacci A, Lazzarini G. Drug delivery by polymeric micelles: an in vitro and in vivo study to deliver lipophilic substances to colonocytes and selectively target inflamed colon. Nanomedicine. 2013;9(5):675–85.
273. Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Deliv. 2013;2013:340315.
274. Lee HJ, Bae Y. Brushed Block Copolymer Micelles with pH-Sensitive Pendant Groups for Controlled Drug Delivery. Pharm Res. 2013;30(8):2077–86.
275. McGuinn WD, Cannon EP, Chui CT, Pei L, Petrikovics I, Way JL. The encapsulation of squid diisopropylphosphorofluoridate-hydrolyzing enzyme within mouse erythrocytes. Fund Appl Toxicol. 1993;21(1):38–43.
276. Yehia SA, Elshafeey AH, Elsayed I. Biodegradable donepezil lipospheres for depot injection: optimization and in-vivo evaluation. J Pharm Pharmacol. 2012;64(10):1425–37.
277. Yehia SA, Elshafeey AH, Elsayed I. A novel injectable in situ forming poly-DL-lactide and DLlactide/glycolide implant containing lipospheres for controlled drug delivery. J Liposome Res. 2012;22(2):128–38.
278. Pandit SS, Patil AT. Formulation and in vitro evaluation of buoyant controlled release lercanidipine lipospheres. J Microencapsul. 2009;26(7):635–41.
279. Attama AA, Okafor CE, Builders PF, Okorie O. Formulation and in vitro evaluation of a PEGylated microscopic lipospheres delivery system for ceftriaxone sodium. Drug Deliv. 2009;16(8):448–57.
280. Hettiarachchi K, Zhang S, Feingold S, Lee AP, Dayton PA. Controllable microfluidic synthesis of multiphase drug-carrying lipospheres for site-targeted therapy. Biotechnol Prog. 2009;25(4): 938–45.
281. Shivakumar HN, Patel PB, Desai BG, Ashok P, Arulmozhi S. Design and statistical optimization of glipizide loaded lipospheres using response surface methodology. Acta Pharm. 2007;57(3):269–85.
282. Fang JY, Hung CF, Liao MH, Chien CC. A study of the formulation design of acoustically active lipospheres as carriers for drug delivery. Eur J Pharm Biopharm. 2007;67(1):67–75.
283. Attama AA, Mpamaugo VE. Pharmacodynamics of piroxicam from self-emulsifying lipospheres formulated with homolipids extracted from Capra hircus. Drug Deliv. 2006;13(2):133–7.
284. Barakat NS, Yassin AE. In vitro characterization of carbamazepine-loaded precifac lipospheres. Drug Deliv. 2006;13(2):95–104.
285. Tursilli R, Casolari A, Iannuccelli V, Scalia S. Enhancement of melatonin photostability by encapsu lation in lipospheres. J Pharm Biomed Anal. 2006;40(4):910–4.
286. Bekerman T, Golenser J, Domb A. Cyclosporin nanoparticulate lipospheres for oral administration. J Pharm Sci. 2004;93(5):1264–70.
287. Sznitowska M, Janicki S, Gajewska M, Kulik M. Investigation of diazepam lipospheres based on Witepsol and lecithin intended for oral or rectal delivery. Acta Pol Pharm. 2000;57(1):61–4.
288. Khopade AJ, Shelly C, Pandit NK, Banakar UV. Liposphere based lipoprotein-mimetic delivery system for 6-mercaptopurine. J Biomater Appl. 2000;14(4):389–98.
289. Capretto L, Mazzitelli S, Colombo G, Piva R, Penolazzi L, Vecchiatini R. Production of polymer ric micelles by microfluidic technology for combined drug delivery: application to osteogenic differentiation of human periodontal ligament mesenchymal stem cells (hPDLSCs). Int J Pharm. 2013;440(2):195–206.
290. Zhang X, Yu P, Han Y, Li Y, Li C. Hydrotropic polymeric mixed micelles based on functional hyperbranched polyglycerol copolymers as hepatoma-targeting drug delivery system. J Pharm Sci. 2013;102(1):145–53.
291. Garg T, Bilandi A, Kapoor B. Scaffold: tissue engineering and regenerative medicine. Int Res J Pharm. 2011;2(12):37–42.
292. Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine. 2009;27(33):4388–401.
293. Kersten GF, Crommelin DJ. Liposomes and ISCOMs. Vaccine. 2003;21(9–10):915–20.
294. Barr IG, Mitchell GF. ISCOMs (immunostimulating complexes): the first decade. Immunol Cell Biol. 1996;74(1):8–25.
295. Mowat AM, Donachie AM. ISCOMS—a novel strategy for mucosal immunization? Immunol Today. 1991;12(11):383–5.
296. Khan F, Islam MS, Roni MA, Jalil RU. Systematic development of self-emulsifying drug delivery systems of atorvastatin with improved bioavailability potential. Sci Pharm. 2012;80(4):1027–43.
297. Mahmoudzadeh M, Fassihi A, Emami J, Davies NM, Dorkoosh F. Physicochemical, pharmaceutical and biological approaches toward designing optimized and efficient hydrophobically modified chitosan-based polymeric micelles as a nanocarrier system for targeted delivery of anticancer drugs. J Drug Target. 2013;21(8):693–709.
298. Saxena V, Hussain MD. Polymeric mixed micelles for delivery of curcumin to multidrug resistant ovarian cancer. J Biomed Nanotechnol. 2013;9(7):1146–54.
299. Gong C, Wu Q, Wang Y, Zhang D, Luo F, Zhao X. A biodegradable hydrogel system containing curcumin encapsulated in micelles for cutaneous wound healing. Biomaterials. 2013;34(27):6377–87.
300. Ju C, Sun J, Zi P, Jin X, Zhang C. Thermosensitive micelles-hydrogel hybrid system based on poloxamer 407 for localized delivery of paclitaxel. J Pharm Sci. 2013;102(8):2707–17.
301. Li G, Meng Y, Guo L, Zhang T, Liu J. Formation of thermo-sensitive polyelectrolyte complex micelles from two biocompatible graft copolymers for drug delivery. J Biomed Mater Res A. 2013.
302. Qin L, Zhang F, Lu X, Wei X, Wang J, Fang X. Polymeric micelles for enhanced lymphatic drug delivery to treat metastatic tumors. J Control Release. 2013;171(2):133–42.
303. Ding J, Li D, Zhuang X, Chen X. Self-Assemblies of pH-activatable PEGylated multiarm poly(lactic acid-co-glycolic acid)-doxorubicin prodrugs with improved long-term antitumor efficacies. Macromol Biosci. 2013;13(10):1300–7.
304. Li D, Sun H, Ding J, Tang Z, Zhang Y, Xu W. Polymeric topology and composition constrained polyether-polyester micelles for directional antitumor drug delivery. Acta Biomater. 2013;9(11):8875–84.
305. Cui C, Xue YN, Wu M, Zhang Y, Yu P, Liu L. Poly(L-aspartamide)-based reduction-sensitive micelles as nanocarriers to improve doxorubicin content in cell nuclei and to enhance antitumor activity. Macromol Biosci. 2013;13(8):1036–47.
306. Wang Y, Ding Y, Liu Z, Liu X, Chen L, Yan W. Bioactive lipids-based ph sensitive micelles for co-delivery of doxorubicin and ceramide to overcome multidrug resistance in leukemia. Pharm Res. 2013;30(11):2902–16.
307. Duan X, Xiao J, Yin Q, Zhang Z, Yu H, Mao S. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano. 2013;7(7):5858–69.
308. Qiao H, Li J, Wang Y, Ping Q, Wang G, Gu X. Synthesis and characterization of multi-functional linear-dendritic block copolymer for intracellular delivery of antitumor drugs. Int J Pharm. 2013;452(1–2):363–73.
309. Desale SS, Cohen SM, Zhao Y, Kabanov AV, Bronich TK. Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer. J Control Release. 2013;171(3):339–48.
310. Johnson RP, Jeong YI, John JV, Chung CW, Kang DH, Selvaraj M. Dual stimuli-responsive poly(Nisopropyl acrylamide)-b-poly(L-histidine) chimeric materials for the controlled delivery of doxorubicin into liver carcinoma. Biomacromolecules. 2013;14(5):1434–43.
311. Wang Y, Wang C, Luo F, Yan X, Qian Z. Micelles of methoxy poly(ethylene glycol)- poly(epsilon-caprolactone) as a novel drug delivery vehicle for tacrolimus. J Biomed Nanotechnol. 2013;9(2):147–57.
312. Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW. Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res. 1992;9(1):87–93.
313. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004;58(3):173–82.
314. Kohli K, Chopra S, Dhar D, Arora S, Khar RK. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today. 2010;15(21–22):958–65.
315. Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm. 2001;212(2):233–46.
316. Vogtle F, Buhleier E, Wehner W. Cascade, Nonskid-chainlike Synthesis of Molecular Cavity Topologies. Synthesis. 1978; 2: 155–8.
317. Garg T, Singh O, Arora S, Murthy R. Dendrimer—a novel scaffold for drug delivery. Int J Pharmaceut Sci Rev Res. 2011;7(2):211–20.
318. Cruz-Bustos T, Gonzalez-Gonzalez G, Morales-Sanfrutos J, Megia-Fernandez A, Santoyo-Gonzalez F, Osuna A. Functionalization of immunostimulating complexes (ISCOMs) with lipid vinyl sulfones and their application in immunological techniques and therapy. Int J Nanomed. 2012;7:5941–56.
319. Hagglund S, Hu K, Vargmar K, Pore L, Olofson AS, Blodorn K. Bovine respiratory syncytial virus ISCOMs-Immunity, protection and safety in young conventional calves. Vaccine. 2011;29(47):8719–30.
320. Pandey RS, Babbar AK, Kaul A, Mishra AK, Dixit VK. Evaluation of ISCOM matrices clearance from rabbit nasal cavity by gamma scintigraphy. Int J Pharm. 2010;398(1–2):231–6.
321. Madsen HB, Ifversen P, Madsen F, Brodin B, Hausser I, Nielsen HM. In vitro cutaneous application of ISCOMs on human skin enhances delivery of hydrophobic model compounds through the stratum corneum. AAPS J. 2009;11(4):728–39.
322. Daines AM, Greatrex BW, Hayman CM, Hook SM, McBurney WT, Rades T. Mannosylated saponins based on oleanolic and glycyrrhizic acids. Towards synthetic colloidal antigen delivery systems. Bioorg Med Chem. 2009;17(14):5207–18.
323. Pham HL, Ross BP, McGeary RP, Shaw PN, Davies NM. Synthesis of cationic derivatives of Quil A and the preparation of cationic immune-stimulating complexes (ISCOMs). Int J Pharm. 2009;376(1–2):123–33.
324. Skene CD, Doidge C, Sutton P. Evaluation of ISCOMATRIX and ISCOM vaccines for immunization against Helicobacter pylori. Vaccine. 2008;26(31):3880–4.
325. Demana PH, Davies NM, Berger B, Rades T. Incorporation of ovalbumin into ISCOMs and related colloidal particles prepared by the lipid film hydration method. Int J Pharm. 2004;278(2):263–74.
326. Lee IA, Popov AM, Sanina NM, Kostetsky EY, Novikova OD, Reunov AV. Morphological and immunological characterization of immunostimulatory complexes based on glycoglycerolipids from Laminaria japonica. Acta Biochim Pol. 2004;51(1):263–72.
327. Sjolander A, Cox JC. Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines. Adv Drug Deliv Rev. 1998;34(2–3):321–38.
328. Copland MJ, Rades T, Davies NM. Hydration of lipid films with an aqueous solution of Quil A: a sim ple method for the preparation of immune-stimulating complexes. Int J Pharm. 2000;196(2):135–9.
329. Morein B, Villacres-Eriksson M, Lovgren-Bengtsson K. Iscom, a delivery system for parenteral and mucosal vaccination. Dev Biol Stand. 1998;92:33–9.
330. Hassan Y, Brewer JM, Alexander J, Jennings R. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems. Vaccine. 1996;14(17–18):1581–9.
331. Ben Ahmeida ET, Gregoriadis G, Potter CW, Jennings R. Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice. Vaccine. 1993;11(13):1302–9.
332. Hu KF, Lovgren-Bengtsson K, Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev. 2001;51(1–3):149–59.
333. Castonguay A, Wilson E, Al-Hajaj N, Petitjean L, Paoletti J, Maysinger D. Thermosensitive dendrimer formulation for drug delivery at physiologically relevant temperatures. Chem Commun (Camb). 2011;47(44):12146–8.
334. Wang Z, Itoh Y, Hosaka Y, Kobayashi I, Nakano Y, Maeda I. Novel transdermal drug delivery system with polyhydroxyalkanoate and starburst polyamidoamine dendrimer. J Biosci Bioeng. 2003;95(5):541–3.
335. Fuchs S, Kapp T, Otto H, Schoneberg T, Franke P, Gust R. A surface-modified dendrimer set for potential application as drug delivery vehicles: synthesis, in vitro toxicity, and intracellular localization. Chemistry. 2004;10(5):1167–92.
336. Gardikis K, Fessas D, Signorelli M, Dimas K, Tsimplouli C, Ionov M. A new chimeric drug delivery nano system (chi-aDDnS) composed of PAMAM G 3.5 dendrimer and liposomes as doxorubicin’s carrier. In vitro pharmacological studies. J Nanosci Nanotechnol. 2011;11(5):3764–72.
337. Ding RM, He H, Li J. [Research progress of polyamidoamine dendrimer in targeting drug delivery system]. Yao Xue Xue Bao. 2011;46(5):493–501.
338. Feng X, Cheng Y, Yang K, Zhang J, Wu Q, Xu T. Host-guest chemistry of dendrimer-drug complexes. Insights into the design of formulations for noninvasive delivery of heparin revealed by isothermal titration calorimetry and NMR studies. J Phys Chem B. 2010;114(34):11017–26.
339. Jakki R, Afzal Syed M, Kandadi P, Veerabrahma K. Development of a self-microemulsifying drug delivery system of domperidone: in vitro and in vivo characterization. Acta Pharm. 2013;63(2): 241– 51.
340. Faisal W, Ruane-O’Hora T, O’Driscoll CM, Griffin BT. A novel lipid-based solid dispersion for enhancing oral bioavailability of lycopene—in vivo evaluation using a pig model. Int J Pharm. 2013;453(2):307–14.
341. Elgart A, Cherniakov I, Aldouby Y, Domb AJ, Hoffman A. Improved oral bioavailability of bcs class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): The Underlying Mechanisms for Amiodarone and Talinolol. Pharm Res. 2013;30(12):3029–44.
342. He S, Cui Z, Mei D, Zhang H, Wang X, Dai W. A cremophor-free self-microemulsified delivery system for intravenous injection of teniposide: evaluation in vitro and in vivo. AAPS PharmSciTech. 2012;13(3):846–52.
343. Prasad D, Chauhan H, Atef E. Studying the effect of lipid chain length on the precipitation of a poorly water soluble drug from self-emulsifying drug delivery system on dispersion into aqueous medium. J Pharm Pharmacol. 2013;65(8):1134–44.
344. Li HQ, Yi T. [Preparation and in vitro characterization of berberine hydrochloride—self-emulsifying microsphere by membrane emulsification technology]. Yao Xue Xue Bao. 2013;48(4):554–9.
345. Jain S, Jain AK, Pohekar M, Thanki K. Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: Implications for drug-induced cardiotoxicity and nephrotoxicity. Free Radic Biol Med. 2013;65C:117–30.
346. Bhattacharyya A, Bajpai M. Oral bioavailability and stability study of a self-emulsifying drug delivery system (SEDDS) of amphotericin B. Curr Drug Deliv. 2013.
347. Cho W, Kim MS, Kim JS, Park J, Park HJ, Cha KH. Optimized formulation of solid self-microemulsifying sirolimus delivery systems. Int J Nanomedicine. 2013;8:1673–82.
348. Monteagudo E, Langenheim M, Salerno C, Buontempo F, Bregni C, Carlucci A. Pharmaceutical optimization of lipid-based dosage forms for the improvement of taste-masking, chemical stability and solubilizing capacity of phenobarbital. Drug Dev Ind Pharm. 2013;40(6):783–92.
349. Seo YG, Kim DH, Ramasamy T, Kim JH, Marasini N, Oh YK. Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect. Int J Pharm. 2013;452(1–2):412–20.
350. Goyal U, Arora R, Aggarwal G. Formulation design and evaluation of a self-microemulsifying drug delivery system of lovastatin. Acta Pharm. 2012;62(3):357–70.
351. Shahba AA, Mohsin K, Alanazi FK. Novel self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of cinnarizine: design, optimization, and in-vitro assessment. AAPS PharmSciTech. 2012;13(3):967–77.
352. Czajkowska-Kosnik A, Sznitowska M, Mirkowska K. Self-emulsifying oils for ocular drug delivery. II. In vitro release of indomethacin and hydrocortisone. Acta Pol Pharm. 2012;69(2):309–17.
353. Baja A, Rao MR, Khole I, Munjapara G. Self-nanoemulsifying drug delivery system of cefpodoxime proxetil containing tocopherol polyethylene glycol succinate. Drug Dev Ind Pharm. 2013;39(5): 635–45.
354. Zarif L. Drug delivery by lipid cochleates. Methods Enzymol. 2005;391:314–29.
355. Goyal AK, Rath G, Garg T. Nanotechnological approaches for genetic immunization. DNA RNA Nanobiotechnol Med. 2013:67–120.
356. Zarif L, Mannino RJ. Cochleates. Lipid-based vehicles for gene delivery-concept, achievements and future development. Adv Exp Med Biol. 2000;465:83–93.
357. Syed UM, Woo AF, Plakogiannis F, Jin T, Zhu H. Cochleates bridged by drug molecules. Int J Pharm. 2008;363(1–2):118–25.
358. Rao R, Squillante E, Kim KH. Lipid-based cochleates: a promising formulation platform for oral and parenteral delivery of therapeutic agents. Crit Rev Ther Drug Carrier Syst. 2007;24(1):41–61.
359. Perlin DS. Amphotericin B cochleates: a vehicle for oral delivery. Curr Opin Investig Drugs. 2004;5(2):198–201.
360. Dung TH, Do le T, Yoo H. PAMAM dendrimer generation 5-pluronic F127 nanofilm as a matrix for local metronidazole release. J Biomed Nanotechnol. 2013;9(7):1286–92.
361. Murugan E, Geetha Rani D, Srinivasan K, Muthumary J. New surface hydroxylated and internally quaternised poly(propylene imine) dendrimers as efficient biocompatible drug carriers of norfloxacin. Expert Opin Drug Deliv. 2013;10(10):1319–34.
362. Agrawal U, Mehra NK, Gupta U, Jain NK. Hyperbranched dendritic nano-carriers for topical delivery of dithranol. J Drug Target. 2013;21(5):497–506.
363. Wang L, Xu X, Zhang Y, Zhu Y, Shi J, Sun Y. Encapsulation of curcumin within poly(amidoamine) dendrimers for delivery to cancer cells. J Mater Sci Mater Med. 2013;24(9):2137–44.
364. Tang J, Chen W, Su W, Li W, Deng J. Dendrimer-encapsulated silver nanoparticles and antibacterial activity on cotton fabric. J Nanosci Nanotechnol. 2013;13(3):2128–35.
365. Kulhari H, Kulhari DP, Prajapati SK, Chauhan AS. Pharmacokinetic and pharmacodynamic studies of poly(amidoamine) dendrimer based simvastatin oral formulations for the treatment of hypercholesterolemia. Mol Pharm. 2013;10(7):2528–33.
366. Choksi A, Sarojini KV, Vadnal P, Dias C, Suresh PK, Khandare J. Comparative anti-inflammatory activity of poly(amidoamine) (PAMAM) dendrimer-dexamethasone conjugates with dexamethasoneliposomes. Int J Pharm. 2013;449(1–2):28–36.
367. Rouhollah K, Pelin M, Serap Y, Gozde U, Ufuk G. Doxorubicin loading, release, and stability of polyamidoamine dendrimer-coated magnetic nanoparticles. J Pharm Sci. 2013;102(6):1825–35.
368. Caballero J, Poblete H, Navarro C, Alzate-Morales JH. Association of nicotinic acid with a poly(amidoamine) dendrimer studied by molecular dynamics simulations. J Mol Graph Model. 2013;39:71–8.
369. Choi SK, Myc A, Silpe JE, Sumit M, Wong PT, McCarthy K. Dendrimer-based multivalent vancomycin nanoplatform for targeting the drug-resistant bacterial surface. ACS Nano. 2013;7(1):214–28.
370. Thiagarajan G, Sadekar S, Greish K, Ray A, Ghandehari H. Evidence of oral translocation of anionic G6.5 dendrimers in mice. Mol Pharm. 2013;10(3):988–98.
371. Ryan GM, Kaminskas LM, Kelly BD, Owen DJ, McIntosh MP, Porter CJ. Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent. Mol Pharm. 2013;10(8):2986–95.
372. Ly TU, Tran NQ, Hoang TK, Phan KN, Truong HN, Nguyen CK. Pegylated dendrimer and its effect in fluorouracil loading and release for enhancing antitumor activity. J Biomed Nanotechnol. 2013;9(2):213–20.
373. Al-Jamal KT, Al-Jamal WT, Wang JT, Rubio N, Buddle J, Gathercole D. Cationic poly-Llysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo. ACS Nano. 2013;7(3):1905–17.
374. Kojima C, Suehiro T, Watanabe K, Ogawa M, Fukuhara A, Nishisaka E. Doxorubicin-conjugated dendrimer/collagen hybrid gels for metastasis-associated drug delivery systems. Acta Biomater. 2013;9(3):5673–80.
375. Sarig H, Ohana D, Epand RF, Mor A, Epand RM. Functional studies of cochleate assemblies of an oligo-acyl-lysyl with lipid mixtures for combating bacterial multidrug resistance. FASEB J. 2011;25(10):3336–43.
376. Livne L, Epand RF, Papahadjopoulos-Sternberg B, Epand RM, Mor A. OAK-based cochleates as a novel approach to overcome multidrug resistance in bacteria. FASEB J. 2010;24(12):5092–101.
377. Sesana AM, Monti-Rocha R, Vinhas SA, Morais CG, Dietze R, Lemos EM. In vitro activity of amphotericin B cochleates against Leishmania chagasi. Mem Inst Oswaldo Cruz. 2011;106(2):251–3.
378. Campo JD, Zayas C, Romeu B, Acevedo R, Gonzalez E, Bracho G. Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses. Methods. 2009;49(4):301–8.
379. Kosloski MP, Peng A, Varma PR, Fathallah AM, Miclea RD, Mager DE. Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates. Drug Deliv. 2011;18(4):246–54.
380. Miclea RD, Varma PR, Peng A, Balu-Iyer SV. Development and characterization of lipidic cochleate containing recombinant factor VIII. Biochim Biophys Acta. 2007;1768(11):2890–8.
381. Santangelo R, Paderu P, Delmas G, Chen ZW, Mannino R, Zarif L. Efficacy of oral cochleate- amp-hote-ricin B in a mouse model of systemic candidiasis. Antimicrob Agents Chemother. 2000;44(9): 2356–60.
382. Perez O, Bracho G, Lastre M, Mora N, del Campo J, Gil D. Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunol Cell Biol. 2004;82(6):603–10.
383. Zayas C, Gonzalez D, Acevedo R, del Campo J, Lastre M, Gonzalez E. Pilot scale production of the vaccine adjuvant proteoliposome derived cochleates (AFCo1) from Neisseria meningitidis serogroup B. BMC Immunol. 2013;14(Suppl 1):S4.
384. Acevedo R, Perez O, Zayas C, Perez JL, Callico A, Cedre B. Cochleates derived from Vibrio cholera O1 proteoliposomes: the impact of structure transformation on mucosal immunisation. PLoS One. 2012;7(10):e46461.
385. Infante-Bourzac JF, Sifontes-Rodriguez S, Arencibia-Arrebola DF, Hernandez-Salazar T, Farinas-Medina M, Perez O. Toxicological assessment of the cochleate derived from Neisseria meningitides proteoliposome in Sprague Dawley rats. N Am J Med Sci. 2012;4(3):135–40.
386. Del Campo J, Lindqvist M, Cuello M, Backstrom M, Cabrerra O, Persson J. Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice. Vaccine. 2010;28(5):1193–200.
387. Romeu B, Gonzalez E, Zayas C, Del Campo J, Acevedo R, Cuello M. AFCo1 as nasal adjuvant of capsular polysaccharide from Neisseria meningitidis serogroup C induces systemic and mucosal immune responses. Scand J Infect Dis. 2011;43(10):809–13.
388. Harris JR, Lewis RJ, Baik C, Pokrajac L, Billington SJ, Palmer M. Cholesterol microcrystals and coch- leate cylinders: attachment of pyolysin oligomers and domain 4. J Struct Biol. 2011;173(1): 38–45.
389. Patel PD, Dand N, Hirlekar RS, Kadam VJ. Drug loaded erythrocytes: as novel drug delivery system. Curr Pharm Des. 2008;14(1):63–70.
390. Hamidi M, Zarrin A, Foroozesh M, Mohammadi-Samani S. Applications of carrier erythrocytes in delivery of biopharmaceuticals. J Control Release. 2007;118(2):145–60.
391. Ihler GM. Pharmacological uses of resealed and modified red cell carriers. Horiz Biochem Biophys. 1989;9:155–84.
392. Gautam S, Barna B, Chiang T, Pettay J, Deodhar S. Use of resealed erythrocytes as delivery system for C-reactive protein (CRP) to generate macrophage-mediated tumoricidal activity. J Biol Response Mod. 1987;6(3):346–54.
393. DeLoach JR, Barton C, Culler K. Preparation of resealed carrier erythrocytes and in vivo survival in dogs. Am J Vet Res. 1981;42(4):667–9.
394. Staros JV, Haley BE, Richards FM. Human erythrocytes and resealed ghosts. A comparison of membrane topology. J Biol Chem. 1974;249(15):5004–7.
395. Shavi GV, Doijad RC, Deshpande PB, Manvi FV, Meka SR, Udupa N. Erythrocytes as carrier for prednisolone: in vitro and in vivo evaluation. Pak J Pharm Sci. 2010;23(2):194–200.
396. Annese V, Latiano A, Rossi L, Lombardi G, Dallapiccola B, Serafini S. Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients-a pilot uncontrolled study. Am J Gastroenterol. 2005;100(6):1370–5.
397. Lizano C, Perez MT, Pinilla M. Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation in vivo survival rate in circulation, organ distribution and ethanol degradation. Life Sci. 2001;68(17):2001–16.
398. Sanz S, Lizano C, Luque J, Pinilla M. In vitro and in vivo study of glutamate dehydrogenase encapsulated into mouse erythrocytes by a hypotonic dialysis procedure. Life Sci. 1999;65(26): 2781–9.
399. Petrikovics I, Cannon EP, McGuinn WD, Pei L, Pu L, Lindner LE. Cyanide antagonism with carrier erythrocytes and organic thiosulfonates. Fundam Appl Toxicol. 1995;24(1):86–93.
400. Pei L, McGuinn WD, Omburo G, Zitzer AH, Petrikovics I, Way JL. Spectrophotometric determination of paraoxonase within mouse carrier red blood cells. Biotechnol Appl Biochem. 1994;20 (Pt 1):35–41.
401. Leung P, Cannon EP, Petrikovics I, Hawkins A, Way JL. In vivo studies on rhodanese encapsulation in mouse carrier erythrocytes. Toxicol Appl Pharmacol. 1991;110(2):268–74.
402. Pei L, Petrikovics I, Way JL. Antagonism of the lethal effects of paraoxon by carrier erythrocytes containing phosphotriesterase. Fundam Appl Toxicol. 1995;28(2):209–14.
403. Pei L, Omburo G, McGuinn WD, Petrikovics I, Dave K, Raushel FM. Encapsulation of phosphotriesterase within murine erythrocytes. Toxicol Appl Pharmacol. 1994;124(2):296–301.
404. Ito Y, Ogiso T, Iwaki M, Kitaike M. Encapsulation of porcine insulin in rabbit erythrocytes and its disposition in the circulation system in normal and diabetic rabbits. J Pharmacobiodyn. 1989;12(4): 193–200.
405. Ito Y, Ogiso T, Iwaki M, Atago H. Encapsulation of human urokinase in rabbit erythrocytes and its disposition in the circulation system in rabbits. J Pharmacobiodyn. 1987;10(10):550–6.
406. Eichler HG, Rameis H, Bauer K, Korn A, Bacher S, Gasic S. Survival of gentamicin-loaded carrier erythrocytes in healthy human volunteers. Eur J Clin Invest. 1986;16(1):39–42.
407. Ogiso T, Iwaki M, Ohtori A. Encapsulation of dexamethasone in rabbit erythrocytes, the disposition in circulation and anti-inflammatory effect. J Pharmacobiodyn. 1985;8(12):1032–40.